Peptides News and Research

RSS

Research findings may lead to treatments for disorders triggered by circadian clock dysfunction

Overnight flights across the Atlantic, graveyard shifts, stress-induced insomnia are all prime culprits in keeping us from getting a good night's sleep. Thanks to new research from McGill University and Concordia University, however, these common sleep disturbances may one day be put to bed.

22 Aug 2013

Clinical trial shows type-1 diabetes patients treated with teplizumab exhibit greater response to therapy

Primary results from a new clinical trial show that patients with type 1 diabetes treated with the monoclonal antibody teplizumab (MacroGenics, Inc.) exhibit greater preservation of C-peptide, a biomarker of islet cell function, compared to controls.

20 Aug 2013

Dermatology researcher receives NIH grant to investigate role of nervous system in psoriasis

Dermatology researcher Nicole Ward, PhD, has earned her third National Institutes of Health grant in a year - including two that scored in the first percentile. With this most recent award, an R21, she will investigate the role the nervous system plays in psoriasis - an inflammatory autoimmune disease characterized by raised areas of red, scaly, itchy and sometimes painful patches of skin.

17 Aug 2013

ATSP-7041 stapled peptide activates p53, suppresses tumor growth in animal models

Aileron Therapeutics, Inc., a clinical stage biopharmaceutical company that is developing first-in-class therapeutics based on its proprietary Stapled Peptide drug platform, announced today the publication of preclinical data on ATSP-7041, a potent and selective stapled peptide re-activator of the wild type p53 tumor suppressor protein.

17 Aug 2013

Researchers discover how common oral bacterium can contribute to colorectal cancer

Researchers from Case Western Reserve University School of Dental Medicine have discovered how a common oral bacterium can contribute to colorectal cancer, a finding that opens promising new research avenues for the development of approaches to prevent and treat the disease.

16 Aug 2013

LMU immunologists develop new technique to fight against tumors, autoimmune diseases

Immunologists at Ludwig-Maximilians-Universitaet (LMU) in Munich have come up with a new technique that can be used both to fight tumors and to treat autoimmune diseases. A new grant from the Federal Ministry for Education and Research will enable the method to be developed further.

14 Aug 2013

New research opens door for development of treatments capable of stopping Alzheimer's disease

New research just out in the journal Science Translational Medicine opens the door for the development of treatments capable of stopping Alzheimer's disease (AD) before its first symptoms, that is to say before any crucial damage occurs. In fact, if AD is a devastating disorder it is also an extremely slow one; it takes more than 10 years for the first symptoms to appear making this preclinical period (pre-symptoms) the ideal time to intervene.

13 Aug 2013

Vitamin D supplementation does not improve blood pressure in hypertension patients

Vitamin D supplementation does not appear to improve blood pressure or markers of vascular health in older patients with isolated systolic hypertension (a common type of high blood pressure), according to a study by Miles D. Witham, Ph.D., of the University of Dundee, Scotland, United Kingdom, and colleagues.

13 Aug 2013

State highlights: Accusations of fraud or abuse in disabled, rehabilitation clinics in N.Y., Mich. and Calif.

Two and a half years ago, The New York Times published an article about abusive employees who worked for the state, detailing how few employees were fired, even after the state recommended that they lose their jobs, because of weaknesses in the arbitration process, the permissive attitude of state officials and the aggressive stance of public sector labor unions -- particularly the Civil Service Employees Association. Gov. Andrew M. Cuomo promised to change all this.

12 Aug 2013

Teplizumab to block type 1 diabetes proves strikingly effective in phase 2 clinical trial

An experimental drug designed to block the advance of type 1 diabetes in its earliest stages has proven strikingly effective over two years in about half of the patients who participated in the phase 2 clinical trial.

8 Aug 2013

Researchers improve efficacy of RASV by modifying pathogen’s ability to survive in hostile environment

The bacterial pathogen Salmonella has a notorious capacity for infection. Last year alone, according to the Center for Disease Control, various species of Salmonella caused multistate disease outbreaks linked with contaminated peanut butter, mangoes, ground beef, cantaloupe, poultry, tuna fish, small turtles and dry dog food.

7 Aug 2013

Bayer Collaboration Could Net $540M+ For Compugen

...

6 Aug 2013

Nano-machine cell killer offers new insight into fight against pathogens

This is a veritable mechanics of aggression on the nanoscale. Certain bacteria, including Staphylococcus aureus, have the ability to deploy tiny darts. This biological weapon kills the host cell by piercing the membrane.

5 Aug 2013

Keeping Alzheimer's disease in check

The future is looking good for drugs designed to combat Alzheimer's disease. EPFL scientists have unveiled how two classes of drug compounds currently in clinical trials work to fight the disease. Their research suggests that these compounds target the disease-causing peptides with high precision and with minimal side-effects.

2 Aug 2013

New approach could provide alternative treatment for chemotherapy-resistant breast cancer

A new way to target a breast cancer cells' appetite for over-indulging in sugar, that could provide an alternative treatment for chemotherapy resistant breast cancer, is being developed by Breast Cancer Campaign scientists at the University of Southampton.

1 Aug 2013

Researchers suggest new key to switch off signaling pathways that lead to hypertension

A team of University of California, San Diego researchers has designed new compounds that mimic those naturally used by the body to regulate blood pressure. The most promising of them may literally be the key to controlling hypertension, switching off the signaling pathways that lead to the deadly condition.

23 Jul 2013

p53 and cancer research: an interview with Professor Sir David Lane, Scientific Director of the Ludwig Institute for Cancer Research

P53 is a tumor suppressor gene. The gene encodes for a protein that monitors the state of the cell. If something goes wrong, it stops the cell from dividing or causes the cell to commit suicide. I call it the “guardian of the genome” as it is the molecule that seems to keep cells normal. It is one of our big defenses against cancer.

22 Jul 2013

Research: Arg-Phe-amide-related peptides may be important regulators of reproductive axis

During the last decade, our understanding of this hypothalamus-pituitary-gonadal axis has quickly expanded.

22 Jul 2013

Study leads to new approach for treatment of aortic valve stenosis

A study conducted by the team of Dr. Jean-Claude Tardif, Director of the Research Centre at the Montreal Heart Institute, has led to the discovery of a new approach to treat aortic valve stenosis through the administration of a compound that prevents valve deterioration and can even reverse the progression of the disease.

19 Jul 2013

TSRI scientists study 3-D structure of glucagon receptor for treatment of diabetes

The study is reported on July 17, 2013, in an advance online edition of the journal Nature, alongside a British laboratory's structural study of another member of the same class of receptors-known as "class B" G protein-coupled receptors (GPCRs).

18 Jul 2013